Becton, Dickinson and Company (NYSE:BDX) declared quarterly dividend of $ 0.79 per share, or $ 3.16 annualized.
The dividend will be payable on September 30, 2020, to stockholders of record on September 9, 2020, with an ex-dividend date of September 8, 2020.
Dividends History
wpDataTable with provided ID not found!Click Here For More Historical Dividends Of Becton, Dickinson and Company
Recent Earnings Announcement
Becton, Dickinson and Company posted income for the second quarter of $ 2.55 per share, from the revenue of $ 4,253.00 million. The quarterly earnings declined 1.54 percent compared with the same quarter last year. According to street consensus, BDX was expected to report 2Q20 income of $ 2.36 per share from revenue of $ 4157.06 million. The bottom line results beat street analysts by $ 0.19 or 8.05 percent, at the same time, top line results outshined analysts by $ 95.94 million or 2.31 percent.
Stock Performance
According to the previous trading day, closing price of BDX was $ 271.89, representing a 37.49 % increase from the 52 week low of $ 197.75 and a 5.17 % decrease over the 52 week high of $ 286.72.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”BDX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
The company has a market capital of $ 81.14 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The companys BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits, reagent systems, bench-side solutions, and molecular indexing and next-generation sequencing sample preparation products, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
